

Hydroxamate-based compounds are potent inhibitors of Toxoplasma gondii HDAC biological activity

Tom Boissavy, Dante Rotili, Thomas Mouveaux, Emmanuel Roger, El Moukthar Aliouat, Christine Pierrot, Sergio Valente, Antonello Mai, Mathieu

Gissot

► To cite this version:

Tom Boissavy, Dante Rotili, Thomas Mouveaux, Emmanuel Roger, El Moukthar Aliouat, et al.. Hydroxamate-based compounds are potent inhibitors of Toxoplasma gondii HDAC biological activity. Antimicrobial Agents and Chemotherapy, In press, 10.1128/aac.00661-23. hal-04252830

HAL Id: hal-04252830 https://hal.science/hal-04252830

Submitted on 21 Oct 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Hydroxamate-based compounds are potent inhibitors of Toxoplasma gondii
2	HDAC biological activity.
3	
4	
5	Tom Boissavy ¹ , Dante Rotili ² , Thomas Mouveaux ¹ , Emmanuel Roger ¹ , El Moukhtar Aliouat ¹ , Christine
6	Pierrot ¹ , Sergio Valente ² , Antonello Mai ² and Mathieu Gissot ^{1,*} .
7	
8	1. Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center
9	for Infection and Immunity of Lille, F-59000 Lille, France.
10	2. Dipartimento di Chimica e Tecnologie del Farmaco "Sapienza" Università di Roma, 00185
11	Rome, Italy.
12	
13	* Corresponding author: <u>mathieu.gissot@pasteur-lille.fr</u>

14 Abstract

Toxoplasmosis is a critical health issue for immune-deficient individuals and the offspring of newly 15 16 infected mothers. It is caused by a unicellular intracellular parasite called Toxoplasma gondii that is 17 found worldwide. Although efficient drugs are commonly used to treat toxoplasmosis, serious adverse events are common. Therefore, new compounds with potent anti-T. gondii activity are needed to 18 19 provide better suited treatments. We have tested compounds designed to target specifically histone 20 deacetylase enzymes. Among the 55 compounds tested, we identified three compounds showing a 21 concentration of drug required for 50% inhibition (IC_{50}) in the low 100 nM range with a selectivity index 22 of more than 100. These compounds are active at inhibiting the growth of the parasite in vitro, but 23 also at preventing some of the consequences of the acute disease in vivo. Two of these hydroxamate 24 based compound also induce a hyper-acetylation of the parasite histones while the parasitic acetylated 25 tubulin level remains unchanged. These findings suggest that the enzymes regulating histone 26 acetylation are potent therapeutic targets for the treatment of acute toxoplasmosis.

27 Introduction

28 Apicomplexa is a phylum of unicellular protozoan parasites that are obligate intracellular and highly 29 transmissible. Among them are several human pathogen species, including Plasmodium spp., 30 Toxoplasma gondii and Cryptosporidium spp. Although toxoplasmosis generally remains symptomless 31 in healthy individuals, it can lead to serious infections in the central nervous system among those with 32 defective immune systems. Additionally, it may result in birth defects or even death in the offspring of 33 newly infected mothers. The prevalence of T. gondii infection worldwide is significant, with estimates 34 indicating that it affects between 30% and 70% of the human population, varying depending on 35 geographical regions (1).

36 T. gondii has a complex life cycle and infection by oocysts or bradyzoites leads to the development of 37 rapidly growing tachyzoites responsible for the clinical manifestations in humans (2). The acute phase 38 of the disease is caused by tachyzoite proliferation, and the latent bradyzoites can persist in the host 39 for prolonged periods, leading to the possibility of reactivation and causing encephalitis, especially in 40 immunocompromised patients (3). The current treatment for toxoplasmosis involves pyrimethamine 41 and sulfadiazine, which target the tachyzoite, but have adverse effects that limit their use. Undesirable 42 side effects are frequently observed with this treatment regimen, with over 30% of patients 43 experiencing adverse events leading to discontinuation of the treatment. Among these, bone marrow 44 suppression is recognized as one of the most severe complications (4). Clindamycin, while being an alternative medication, carries comparable risks of side effects and is less effective in preventing 45 46 relapse (5). Additionally, there are presently no treatments available that specifically target the 47 bradyzoite, which is the dormant form of the parasite found in intermediate hosts, including humans.

To address the need for a better treatment, compounds targeting epigenetic mechanisms have been tested against *T. gondii* (6). Enzymes mediating epigenetic modifications of histones have been shown to be promising therapeutic targets (7). Indeed, the control of gene expression is essential to the survival of parasites and more acutely during growth phases (8, 9). Histone acetylation has been extensively investigated as a targeted epigenetic mechanism for identifying compounds that inhibit *T*. 53 qondii (10) and other parasites (11). Enzymes involved in the regulation of histone acetylation have 54 been identified as promising therapeutic targets since several modulators of these enzymes were 55 shown to bear an activity against T. gondii (6, 12–14). In particular, several inhibitors of histone 56 deacetylases (HDAC) have been shown to suppress the tachyzoite growth in vitro (6, 12, 15–18) 57 indicating that these enzymes are key for the survival of this fast-growing form of the parasite. 58 Moreover, an hydroxamate-based HDAC inhibitor (HDACi) belonging to the uracil-based hydroxyamide 59 (UBHA) class (19), MC1742, was also active in vivo to prevent the consequences of the acute disease 60 in a mouse model of toxoplasmosis (6) and is active against other apicomplexan parasites as 61 Plasmodium falciparum, the causative agent of malaria (20). MC1742 treatment of T. gondii 62 tachyzoites resulted in elevated levels of parasite histone acetylation, significantly influencing gene 63 expression (6). These findings strongly indicate that histone deacetylation plays a vital role in sustaining 64 the specific gene expression program during the tachyzoite phase (6).

65 In this manuscript, we aimed at discovering new compounds that would show an anti-T. gondii activity 66 both in vitro and in vivo. We investigated the anti-T. gondii activity of hydroxamate-based compounds 67 that were designed to target the HDAC activity. We tested more than 50 compounds and 68 demonstrated that more than 30 compounds showed potent activity against the tachyzoite form of this parasite in vitro. Two compounds presented a concentration of drug required for 50% inhibition 69 70 (IC₅₀) lower than that of other hydroxamate-based HDACi, including MC1742. Treatment with these 71 two inhibitors strongly increased the level of parasite histone acetylation indicating that they were 72 bona fide HDACi of the parasite. They were also shown to limit the consequences of acute 73 toxoplasmosis in a mouse model of the disease indicating that hydroxamate HDACi are interesting 74 candidates to further expand the therapeutic arsenal against T. gondii.

75 Material and methods

76 Parasite strains and culture

Toxoplasma gondii tachyzoites of the type I (RH and RH-LUC GFP (21)) and type II (76K and PTG-LUC GFP (21)) strains were propagated *in vitro* in human foreskin fibroblasts (HFF) using Dulbeccos's
 modified Eagles medium supplemented with 10% fetal calf serum (FCS), 2mM glutamine, and 1%
 penicillin-streptomycin (complete media). Tachyzoites were grown in ventilated tissue culture flasks
 at 37°C and 5% CO₂. The luciferase gene is expressed under the control of the *tubulin* promoter and is
 therefore expressed in both tachyzoites and bradyzoites (21).

83 Compounds.

The structures, source, references and molecular weight for all HDAC inhibitors used in the study are listed in the Supplementary Tables S1-S4. All compounds were originally dissolved in 100% dimethyl sulfoxide (DMSO) to a 20 mM stock solution. For *in vitro* experiments, the stock solutions were diluted in complete media to the required concentrations. For *in vivo* experiments, the stock solutions were diluted in PBS before injection. Solutions at the final concentration were prepared just before use. Pyrimethamine was resuspended in DMSO to a 7 mg/mL concentration.

90 Immunofluorescence analysis (IFAs)

91 HFF cells were infected with *T. gondii* tachyzoites of the RH strain for 24 hours in presence of the 92 compound or solvent and then fixed using 4% (paraformaldehyde) (PFA) for 30 minutes. The coverslips 93 were incubated with primary antibodies (Table S5) and then secondary antibodies coupled to Alexa 94 Fluor-488 or Alexa-Fluor-594. Confocal imaging was performed with a ZEISS LSM880 Confocal 95 Microscope. All images were processed using Carl Zeiss ZEN software. Manual counting of the number 96 of parasites per vacuole was carried out on at least 100 vacuoles for each biological replicate (n=3).

97 In vitro anti-T. gondii activity

98 IC_{50} measurement of each compound was carried out using a luminometric assay using strains 99 expressing luciferase (RH-LUC GFP or the PTG-LUC GFP) as previously described (6). Briefly, 10

100 compound concentrations were tested in triplicate from 2 μ M to 1 nM, since we aimed at identifying 101 compounds that showed a better IC₅₀ than Pyrimethamine (660 nM as shown before (6)). Readings 102 were performed after 24 or 40 hours for the type I or II strain, respectively. The parasite proliferation 103 was measured by detecting the emission of light on a SPARK plate reader (TECAN). Graphpad Prism 104 was used to plot a regression curve and calculate the IC₅₀ for each compound.

105 Measurements of cytotoxic activity

106 HepG2 (liver hepatocellular carcinoma cells) and HFF (Human Foreskin Fibroblast) cells were used in 107 this assay. Alamar Blue® assay is an oxidation-reduction indicator that reflects the compounds 108 cytotoxicity. Cells were seeded in 96 wells plates and incubated with various concentrations (from 100 109 nM to 100 µM) of compounds in triplicates for 72h in 200 µL total volume. Then, 20µL of Alamar Blue™ 110 HS cell viability reagent (Invitrogen) was added to the wells. After 24h of incubation, the samples' 111 absorbance was measured using the SPARK plate reader (TECAN) at 570 nm and 600 nm. Wells without 112 cells and with or without Alamar Blue[™]HS reagent were used to account for background. Cells 113 incubated with various concentrations of solvent (DMSO; 0,8 % to 0,006 % (vol/vol).) were used as 114 controls. Different concentrations (400 μ M to 3,125 μ M) of chloroquine, that has an known IC₅₀ on 115 HFF cells (20), were used as an internal control. The measurements were analyzed as a dose-response 116 curve to determine the IC₅₀. Each experiment was performed in triplicate. The IC₅₀ were calculated 117 using the online calculator available at <u>https://www.aatbio.com/tools/ic50-calculator.</u>

118 Measurement of *in vivo* observable adverse effect level of the compounds

To evaluate if the compound would have deleterious visible effects on mice health and behavior, we treated 5 six-weeks old Balb/c mice intraperitoneally with either DMSO (a 7% solution in PBS) or the compounds (MC2590, MC2059 or MC2125) at different doses (10, 30 or 60 mg/kg), daily, for 5 days. As a measure of their global health status, we measured their weight and followed signs of modification of their grooming and exploration behavior following the scoring table as described in Table S6. A global score was recorded for each mouse daily for 15 days.

125 In vivo anti T. gondii activity in a mouse model

126 The Institut Pasteur de Lille's ethical committee approved the animal housing and experimentation 127 conditions in accordance with the French Council in Animal Care guidelines for the care and use of 128 animals (protocol #11082-2017072816548341 v2). Six to eight weeks old Balb/c mice were injected intraperitoneally with a 10^5 parasites dose (in 200 μ L) of the 76K strain. The next day, the mice were 129 130 injected intraperitoneally with different quantity of compounds (200 μ L in a 7% DMSO solution), daily, 131 for 5 days. Pyrimethamine was administered in tap water using a 100 times dilution of the stock solution (7mg/mL) diluted in tap water. Differences in survival curves were assessed by a Log-rank 132 133 (Mantel-Cox) test with a minimal number of 15 mice per group.

134 Primary neurons infections and bradyzoite in vitro targeting assay

Neo-natal rat brain cells were collected from hippocampus and seeded as described in (22). After 14 days of maturation, the primary brain cells were infected using 5000 parasites, of the PTG-LUC-GFP strain, per well of a 24 well plate at a MOI of 0.1. Fourteen days later, the infected primary cell culture was incubated with a compound ((MC2590, MC2059 or MC2125) concentration of to 3 times the IC_{50} (as determined above against the tachyzoite stage) or an equivalent volume of DMSO. The culture was left for 7 more days and was then collected and lysed in 100 µL of lysis buffer and processed as described before for luciferase detection.

142 Western-Blot

143 Intracellular RH strain parasites were grown for 24 hours and then treated over-night (15 hours) with 144 0.5 µM of MC2590, MC2125, MC2059 or DMSO. Parasites were then purified by sequential syringe 145 passage with 17-gauge and 26-gauge needles and filtration through a 3-µm polycarbonate membrane 146 filter. This allowed the collection of parasites free from the host-cell material. To prepare the total 147 protein extracts, parasites were resuspended in 1X Laemmli buffer. These samples were then 148 fractionated on a 15% SDS-polyacrylamide electrophoresis gel. The antibodies are listed in Table S5. 149 Chemiluminescent detection of bands was carried out using Super Signal West Femto Maximum 150 Sensitivity Substrate.

151 Statistics and Reproducibility

- 152 All data were analyzed with GraphPad Prism software version 8. Differences in the means were
- assessed by Student's t-test. Differences in survival curves were assessed by a Log-rank (Mantel-Cox)
- test. In all cases, p-values are two-sided and P < 0.05 was considered as significant. All experiments
- 155 were repeated at least three times using biologically independent replicates.

156 Results

157 Compounds potentially active against HDAC inhibit tachyzoite growth.

158 HDACi have been shown to have a potent activity against *T. gondii*. In particular, hydroxamate-based 159 HDACi were shown to have an activity in vitro and in vivo against the tachyzoite stage of this parasite 160 (6). Therefore, we tested internal library of more than 50 hydroxamate-based compounds that 161 potentially targeted HDACs for their anti-T. gondii activity (Figure 1A). These compounds have different 162 structures but all have a backbone bearing an hydroxamic acid (Supplementary Table 1, 2, 3 and 4). To 163 do this, we first investigated their ability to inhibit the parasite proliferation in its tachyzoite form in 164 vitro. We used a luciferase expressing type II parasite strain to take advantage of the large linear range 165 of detection of luminescence. We compared the compounds calculated IC₅₀s to the clinically relevant 166 pyrimethamine, another hydroxamate based HDACi (suberoylanilide hydroxamic acid; SAHA) and the 167 previously identified HDACi MC1742 (6). Among these compounds, 14 had an IC₅₀ higher than 1500 168 nM and therefore could not be exactly measured using the dilution range used in this assay (Figure 169 1A). Three other compounds showed an IC_{50} higher than pyrimethamine (660 nM). We found 35 170 potential HDACi exhibiting a lower IC₅₀ in vitro than pyrimethamine indicating the strong inhibitory 171 potential of HDACi against the tachyzoite stage of *T. gondii* (Figure 1A and Supplementary Table 1). 172 Three compounds (MC2125, MC2590 and MC2059) with a potential anti-HDAC activity were shown to have similar or lower IC_{50} than MC1742 and lower IC_{50} than SAHA, an hydroxamate-based HDACi that 173 174 have been shown to inhibit parasite growth (Table 1). MC2125 is structurally similar of MC1742, but present a 6-time lower IC₅₀. MC2590 is an hydroxamate-based compound that has been shown to 175 176 potentially target human HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC₅₀s of 15-156 177 nM (23). MC2590 also inhibits human HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with 178 IC₅₀s of 1350-3890 nM (23). MC2059 is also an hydroxamate-based compound and has been shown to 179 have an HDACi activity in vitro (24).

180 We confirmed the compounds anti-tachyzoite activity *in vitro* using IFA (Figure 1B). The mean parasite
181 number per vacuole was assessed in presence of the compounds. When treated by solvent control

(DMSO), the parasites grew to a mean of 14 parasites per vacuole. The MC2125, MC2590 and MC2059 treatment resulted in a strong decrease of the number of parasites per vacuole confirming that the compound can reach the parasite (and pass through the parasite vacuole) (Figure 1B). We also found that the parasites showed different phenotypes depending on which compound was used (Figure S1), but growth arrest due to defects in the cell cycle were apparent in all cases.

We measured the IC₅₀ of these compounds on type I or type II parasites and found similar results for
both types, indicating the activity of the compounds was almost identical on different strains (Table
2).

190 Selected compounds present a good selectivity index.

191 To ensure that the selected compounds did not show cytotoxicity at the tested concentration, we 192 measured the IC_{50} of these compounds against two cell types using the Alamar blue assay. The 193 cytotoxicity of the compounds was measured on human foreskin fibroblasts (HFF) and on HepG2 cells, 194 a hepatocellular carcinoma cell line. We were therefore able to calculate the selectivity index (SI) of 195 these compounds and compare it to that of MC1742 (Table 2). Overall, MC2125, MC2590 and MC2059 196 showed better SI than MC1742 with SI values above 200. However, HepG2 cells were more sensitive 197 to these compounds and the calculated SI values were dropped to 40, 111 and 240 for MC2125, 198 MC2059 and MC2590, respectively. Although MC2125 was the most efficient compound on tachyzoite 199 growth, it was also more cytotoxic than the other two compounds (Table 2).

200 MC2125 and MC2590 are a potent inhibitors of the parasite HDACs.

MC1742 is an inhibitor of human class I/IIb HDACs (25) and *T. gondii* HDACs (6). To indirectly evaluate the HDACi activity of MC2125, MC2059, MC2590, and as a negative control, DMSO, we examined the comparative acetylation levels of various parasite histones following treatment. For that, we checked the relative acetylation level of Histone H4 (acH4 and H4K8ac) and Histone H3 (H3K9ac and H3K18ac). The level of methylation of Histone H3 at the lysine 4 position (H3K4me3) was also measured by Western-blot. MC2125 and MC2590 treatment induced a significant increase of acetylation of both

histone H3 and H4, while the level of H3K4me3 was unchanged (Figure 2). In contrast, MC2059 had no
effect on the acetylation levels and therefore may not target the parasites HDACs (Figure 2 and S2).
We also verified the level of acetylation of tubulin at the lysine 40 position by Western-blot and showed
that the compound did not significantly influence the acetylation of this non-histone parasite protein.

211 MC2590 is effective at preventing acute disease

In order to assess the maximum dose that we could inject to mice without visual deleterious effects on mice behavior and health, we injected different concentration of compounds to mice and followed their body weight and behavior during 15 days (Figure S3). This experiment showed that injecting 60 mg/kg of MC2059, 30mg/kg of MC2590 or 10mg/kg of MC2125 had no observable effect on mice weight (Figure S3A) and behavior (Figure S3B). However, increasing the concentration of MC2125 to 30mg/kg was deleterious to mice (Figure S3).

218 To assess the ability of MC2125, MC2059 and MC2590 to prevent the outcome of the acute disease in 219 a mouse model, we infected Balb/c mice with a lethal dose (10⁵ parasites) of *T. gondii* type II strain. 220 We then recorded the survival of mice for 15 days (Figure 3A). In the control group (n=15), the survival 221 rate was 0 %. Mice treated with MC2059 at either 30 mg/kg or 60 mg/kg did not survive the acute 222 infection. In contrast, the mice treated with MC2125 did show a slight improvement in their ability to 223 limit the consequences of the acute infection with 20 % of the mice surviving in the 10 mg/kg group 224 (15 mice). Finally, MC2590 (30mg/kg) was the most efficient compound and increased the survival to 225 60% of the mice (n=15) indicating that MC2590 was efficient at preventing the outcome of the acute 226 disease in this mouse model (Figure 3A). However, none of these compounds was as efficient as 227 pyrimethamine.

228 The tested compounds fail to reduce cyst burden in vitro.

To test the effect of these molecules on the established chronic form of the parasite, we took advantage of the recently established primary brain cell model, that mimics *in vitro* the production of mature bradyzoite cysts, the latent form of the parasite (22). This new *in vitro* model is an efficient

alternative to the usage of mice to assess the compound ability to target established cysts. As observed
previously for MC1742 (6), the HDACi tested here were not effective at eliminating the established
cysts. Indeed, treatment with these compounds only marginally impacted the presence of bradyzoite
cysts in the culture when compared to the DMSO treated culture and as measure by luminescence
(Figure 3B).

237 Discussion

238 We explored the anti-T. gondii activity of compounds targeting HDACs. T. gondii encodes 5 potential 239 HDACs (TgHDAC1 to 5) which are expressed at the tachyzoite and bradyzoite stage (22) and at least 4 240 of them show negative fitness scores in CrispR/Cas9 screen targeting tachyzoites (26), indicating their 241 importance at these stages of the parasite life cycle. These enzymes are implicated in the process of 242 regulating the establishment and maintenance of gene expression profiles during the life cycle of the 243 parasite, a mechanism that is likely crucial for adaptation to changing environments (8). The fact that 244 these compounds might be crucial for the parasite's life cycle and the potential for repurposing them 245 as drugs makes them appealing targets for further investigation. It has been shown that other HDACi 246 have a potent activity against *T. gondii* and other apicomplexan parasites (20). Here, we tested more 247 than 50 compounds potentially targeting parasite HDACs (Supplementary Table 1). Among these, 35 248 compounds exhibited a lower IC_{50} in vitro than pyrimethamine, the clinically relevant drug to treat 249 toxoplasmosis. All of these compounds presented an hydroxamate group (Supplementary Table 1) that 250 is known to inhibit metalloproteases or zinc hydrolases like HDACs (27). The high potency of these 251 hydroxamate-based compounds against *T. gondii* tachyzoite growth suggests that this chemical group 252 is a strong inhibitor of these enzymes in this parasite. Interestingly, the other -hydroxamate-based 253 HDACi vorinostat (SAHA) is already approved by the FDA for the treatment of cancers (28) and has 254 been shown to be active against Cryptosporidium parvum (29) in vivo and T. gondii (6, 12) in vitro, 255 suggesting that it could be repurposed to treat parasitic diseases caused by apicomplexan parasites. 256 Surprisingly, hydroxamate-based compounds were shown to have an IC₅₀ in the low nanomolar range 257 against P. falciparum, but were unable to inhibit the growth of the P. berghei in vivo (20). This may be 258 due to the poor pharmacokinetics properties of many hydroxamates (30). Establishing the 259 pharmacokinetic paramaters for these compounds could guide the design of further in vivo 260 experiments. In contrast, MC1742 (6) and to a lesser extent MC2590 (this study) was able to limit the 261 consequences of acute toxoplasmosis in vivo. Further research is warranted to improve these 262 compounds activity and bioavailability.

263 Although, MC2590 and MC1742 were efficient at preventing the outcome of the acute disease, neither 264 of these potential HDACi were able to eliminate the latent form of the parasite once established as it 265 was shown in vivo for MC1742 (6) and in vitro for MC2590 (this study). It was speculated previously 266 that MC1742 may have low availability and/or concentration of the molecule in the brain where 267 bradyzoite cysts reside since this experiment was performed in vivo (6). However, using the newly in 268 vitro model to produce bradyzoite cysts (22), we were able to show that the tested inhibitors had a 269 poor activity against these encysted latent forms (Figure 3B). This suggests that using hydroxamate-270 based HDACi may not be of interest to target these forms. The bradyzoites are surrounded by a thick 271 cyst wall that lies underneath the membrane of the parasitophorous vacuole and it is unclear how 272 permeable this structure is. Indeed, our results suggest that hydroxamate compounds are not able to 273 reach the bradyzoites. Alternatively, HDAC activity may not be essential at this latent stage of the life 274 cycle. Only a handful of compounds were shown to reduce cyst burden (31, 32). Consequently, there 275 is a need to develop novel in vitro systems enabling the testing compounds against bradyzoites. The 276 exploration of organoids or in vitro cultures of primary brain or muscle cells holds the potential to 277 unlock this new research pathway (22, 33).

278 Surprisingly, MC2059, a compound that has been shown to target human HDACs (24) was not able to 279 induce an hyperacetylation of T. gondii histones or tubulin (Figure 2C). This indicates that this 280 compound may have another target in the parasite. Hydroxamate-based compounds can inhibit 281 metalloproteases or zinc hydrolases (27) and MC2059 may target these enzymatic activities. 282 Alternatively, MC2059 may have an indirect effect on parasite growth through the inhibition of the 283 human host HDAC activities. This may be also the case for MC2125 and MC2590, that have been proven 284 to target the parasite HDACs, as the parasite is treated as well as the host. In the future, it would be of 285 interest to identify the consequences of the compound treatment on the host and measure the gene 286 expression perturbations induced by these HDACi at low concentration where no cytotoxic effect is 287 visible on host cells. We have found that MC2125 had a cytotoxic effect on HepG2 cells at a 100 nM 288 concentration, indicating that low concentration of these HDACi may have a direct consequence on

host cells, depending on their cellular type. Moreover, increasing the MC2125 dose to 30 mg/kg
showed deleterious visible effects on mice, indicating that the dose could not be increased.

291 Among the compounds tested in the study, MC2590 proved to be the most potent. It displayed 292 significant efficacy in inhibiting growth in vitro, exhibiting an IC₅₀ lower than pyrimethamine, other 293 hydroxamate-based HDACi, and similar to that of MC1742. It also presents an attractive selectivity 294 index and may target parasitic HDACs. Therefore, MC2590 is another example of an hydroxamate-295 based HDACi with a potent activity against this parasite and also highlights the importance of these 296 enzymatic activities for the survival of T. gondii tachyzoites in vitro. MC2590 was also effective at 297 preventing the outcome of the acute disease, although to a lesser extent than MC1742. These HDACi 298 are therefore promising compounds to treat acute toxoplasmosis. However, they need to be 299 chemically improved to match the *in vivo* activity of pyrimethamine.

300 In summary, we have discovered an HDAC inhibitor that demonstrates strong anti-*T. gondii* activity 301 both *in vitro* and *in vivo*, as evidenced by its efficacy in a mouse model of acute disease. MC2590 is a 302 promising compound for future treatment of the acute phase of toxoplasmosis.

303 Funding

This work was supported by Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), and a Region Haut de France together with iSITE grant (START-AIRR) to MG.

307 Acknowledgments

308 The authors wish to thank the BioImaging Center Lille for access to instruments.

309 **Bibliography**

1. Montoya, J.G. and Liesenfeld, O. (2004) Toxoplasmosis. *Lancet Lond. Engl.*, **363**, 1965–1976.

2. Kim,K. and Weiss,L.M. (2004) Toxoplasma gondii: the model apicomplexan. *Int J Parasitol*, **34**, 423–
 32.

- 313 3. Munoz, M., Liesenfeld, O. and Heimesaat, M.M. (2011) Immunology of Toxoplasma gondii. *Immunol.* 314 *Rev.*, 240, 269–285.
- 4. Ben-Harari,R.R., Goodwin,E. and Casoy,J. (2017) Adverse Event Profile of Pyrimethamine-Based
 Therapy in Toxoplasmosis: A Systematic Review. *Drugs RD*, **17**, 523–544.
- 5. Katlama,C., De Wit,S., O'Doherty,E., Van Glabeke,M. and Clumeck,N. (1996) Pyrimethamineclindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic
 encephalitis in patients with AIDS. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.*, 22, 268–
 275.
- 6. Mouveaux,T., Rotili,D., Boissavy,T., Roger,E., Pierrot,C., Mai,A. and Gissot,M. (2022) A potent
 HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite
 gene expression. *Int. J. Antimicrob. Agents*, **59**, 106526.
- 324 7. Alday, P.H. and Doggett, J.S. (2017) Drugs in development for toxoplasmosis: advances, challenges,
 325 and current status. *Drug Des. Devel. Ther.*, **11**, 273–293.
- 8. Gissot, M., Kim, K., Schaap, D. and Ajioka, J.W. (2009) New eukaryotic systematics: a phylogenetic
 perspective of developmental gene expression in the Apicomplexa. *Int. J. Parasitol.*, **39**, 145–
 151.
- 9. Gissot, M. and Kim, K. (2008) How epigenomics contributes to the understanding of gene regulation
 in Toxoplasma gondii. *J. Eukaryot. Microbiol.*, **55**, 476–480.
- 10. Vanagas, L., Jeffers, V., Bogado, S.S., Dalmasso, M.C., Sullivan, W.J. and Angel, S.O. (2012)
 Toxoplasma histone acetylation remodelers as novel drug targets. *Expert Rev. Anti Infect. Ther.*, 10, 1189–1201.
- 11. Fioravanti, R., Mautone, N., Rovere, A., Rotili, D. and Mai, A. (2020) Targeting histone
 acetylation/deacetylation in parasites: an update (2017-2020). *Curr. Opin. Chem. Biol.*, 57,
 65–74.
- 12. Araujo-Silva,C.A., De Souza,W., Martins-Duarte,E.S. and Vommaro,R.C. (2021) HDAC inhibitors
 Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii
 chemotherapeutics. *Int. J. Parasitol. Drugs Drug Resist.*, **15**, 25–35.
- 340 13. Jeffers, V., Gao, H., Checkley, L.A., Liu, Y., Ferdig, M.T. and Sullivan, W.J. (2016) Garcinol Inhibits
 341 GCN5-Mediated Lysine Acetyltransferase Activity and Prevents Replication of the Parasite
 342 Toxoplasma gondii. *Antimicrob. Agents Chemother.*, 60, 2164–2170.
- 14. Hailu,G.S., Robaa,D., Forgione,M., Sippl,W., Rotili,D. and Mai,A. (2017) Lysine Deacetylase
 Inhibitors in Parasites: Past, Present, and Future Perspectives. J. Med. Chem., 60, 4780–4804.
- 345 15. Zhang,Y., Zhang,Q., Li,H., Cong,H. and Qu,Y. (2022) In vitro and in vivo anti-Toxoplasma activities
 346 of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis. *Front. Cell.* 347 *Infect. Microbiol.*, **12**, 1002817.
- 16. Loeuillet, C., Touquet, B., Oury, B., Eddaikra, N., Pons, J. L., Guichou, J. F., Labesse, G. and Sereno, D.
 (2018) Synthesis of aminophenylhydroxamate and aminobenzylhydroxamate derivatives and in vitro screening for antiparasitic and histone deacetylase inhibitory activity. *Int. J. Parasitol. Drugs Drug Resist.*, **8**, 59–66.

- 17. Jublot, D., Cavaillès, P., Kamche, S., Francisco, D., Fontinha, D., Prudêncio, M., Guichou, J.-F.,
 Labesse, G., Sereno, D. and Loeuillet, C. (2022) A Histone Deacetylase (HDAC) Inhibitor with
 Pleiotropic In Vitro Anti-Toxoplasma and Anti-Plasmodium Activities Controls Acute and
 Chronic Toxoplasma Infection in Mice. *Int. J. Mol. Sci.*, 23, 3254.
- 18. Bougdour,A., Maubon,D., Baldacci,P., Ortet,P., Bastien,O., Bouillon,A., Barale,J.-C., Pelloux,H.,
 Ménard,R. and Hakimi,M.-A. (2009) Drug inhibition of HDAC3 and epigenetic control of
 differentiation in Apicomplexa parasites. J. Exp. Med., 206, 953–966.
- 19. Mai,A., Massa,S., Rotili,D., Pezzi,R., Bottoni,P., Scatena,R., Meraner,J. and Brosch,G. (2005)
 Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil based hydroxamates. *Bioorg. Med. Chem. Lett.*, **15**, 4656–4661.
- 362 20. Bouchut,A., Rotili,D., Pierrot,C., Valente,S., Lafitte,S., Schultz,J., Hoglund,U., Mazzone,R., Lucidi,A.,
 363 Fabrizi,G., *et al.* (2019) Identification of novel quinazoline derivatives as potent
 364 antiplasmodial agents. *Eur. J. Med. Chem.*, **161**, 277–291.
- 365 21. Saeij, J.P.J., Boyle, J.P., Grigg, M.E., Arrizabalaga, G. and Boothroyd, J.C. (2005) Bioluminescence
 366 imaging of Toxoplasma gondii infection in living mice reveals dramatic differences between
 367 strains. *Infect. Immun.*, **73**, 695–702.
- 368 22. Mouveaux, T., Roger, E., Gueye, A., Eysert, F., Huot, L., Grenier-Boley, B., Lambert, J.-C. and Gissot, M.
 369 (2021) Primary brain cell infection by Toxoplasma gondii reveals the extent and dynamics of
 370 parasite differentiation and its impact on neuron biology. *Open Biol.*, **11**, 210053.
- 23. Di Bello, E., Sian, V., Bontempi, G., Zwergel, C., Fioravanti, R., Noce, B., Castiello, C., Tomassi, S.,
 Corinti, D., Passeri, D., *et al.* (2023) Novel pyridine-containing histone deacetylase inhibitors
 strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells. *Eur. J. Med. Chem.*, **247**, 115022.
- 24. Di Bello, E., Noce, B., Fioravanti, R., Zwergel, C., Valente, S., Rotili, D., Fianco, G., Trisciuoglio, D.,
 Mourão, M.M., Sales, P., *et al.* (2022) Effects of Structurally Different HDAC Inhibitors against
 Trypanosoma cruzi, Leishmania, and Schistosoma mansoni. *ACS Infect. Dis.*, **8**, 1356–1366.
- 25. Di Pompo,G., Salerno,M., Rotili,D., Valente,S., Zwergel,C., Avnet,S., Lattanzi,G., Baldini,N. and
 Mai,A. (2015) Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and
 differentiation in sarcoma cancer stem cells. J. Med. Chem., 58, 4073–4079.
- Sidik,S.M., Huet,D., Ganesan,S.M., Huynh,M.-H., Wang,T., Nasamu,A.S., Thiru,P., Saeij,J.P.J.,
 Carruthers,V.B., Niles,J.C., *et al.* (2016) A Genome-wide CRISPR Screen in Toxoplasma
 Identifies Essential Apicomplexan Genes. *Cell*, **166**, 1423-1435.e12.
- 27. Lou, B. and Yang, K. (2003) Molecular diversity of hydroxamic acids: part II. Potential therapeutic
 applications. *Mini Rev. Med. Chem.*, **3**, 609–620.
- 28. Marks, P.A. and Breslow, R. (2007) Dimethyl sulfoxide to vorinostat: development of this histone
 deacetylase inhibitor as an anticancer drug. *Nat. Biotechnol.*, **25**, 84–90.
- 388 29. Guo, F., Zhang, H., McNair, N.N., Mead, J.R. and Zhu, G. (2018) The Existing Drug Vorinostat as a
 389 New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases. J. Infect.
 390 Dis., 217, 1110–1117.

- 30. Flipo,M., Charton,J., Hocine,A., Dassonneville,S., Deprez,B. and Deprez-Poulain,R. (2009)
 Hydroxamates: Relationships between Structure and Plasma Stability. *J. Med. Chem.*, 52,
 6790–6802.
- 31. Martynowicz, J., Doggett, J.S. and Sullivan, W.J. (2020) Efficacy of Guanabenz Combination Therapy
 against Chronic Toxoplasmosis across Multiple Mouse Strains. *Antimicrob. Agents Chemother.*, 64.
- 32. Doggett, J.S., Schultz, T., Miller, A.J., Bruzual, I., Pou, S., Winter, R., Dodean, R., Zakharov, L.N.,
 Nilsen, A., Riscoe, M.K., *et al.* (2020) Orally Bioavailable Endochin-Like Quinolone Carbonate
 Ester Prodrug Reduces Toxoplasma gondii Brain Cysts. *Antimicrob. Agents Chemother.*, 64.
- 33. Christiansen, C., Maus, D., Melerowicz, F., Scholz, J., Murillo-León, M., Steinfeldt, T., Hoffmann, T.,
 Seeber, F. and Blume, M. (2021) A Novel in vitro Model for Mature Toxoplasma gondii
 Bradyzoites Reveals their Metabolome and a Diminished Role of the Mitochondrial
 Tricarboxylic Acid Cycle. *bioRxiv*, 10.1101/2021.01.15.426845.
- 404

405 Figure legends

406 Figure 1: Compounds potentially active against HDACs inhibit tachyzoite growth. (A) Calculated IC₅₀ 407 for each tested compound. Intracellular tachyzoite of the type II strain PTG-LUC GFP were treated for 408 40 hours at different concentrations (from 2μ M to 2nM). The mean IC₅₀ for three biological replicates 409 is presented on the graph together with SD. Compounds were ranked based on their calculated IC₅₀. The IC₅₀ values for Pyrimethamine (red), MC1742 (green), MC2059 (purple), MC2590 (orange) and 410 MC2125 (blue) are highlighted in the graph. Mean \pm SD (n=3 independent experiments). (B) Effect of 411 412 the compounds on RH tachyzoites on intracellular growth. Tachyzoite intracellular growth was 413 measured after 36 hours of exposure to different compounds at 2 times the IC_{50} concentration. The 414 average number of parasites per vacuole is used as a metric of parasite intracellular growth and 415 measured by IFAs. Parasites treated with DMSO (blue bars) are used as a control. We measured the effect of MC2059 (red bars), MC2590 (green bars), MC2125 (purple bars) on intracellular growth. A 416 Student's t-test was performed with the DMSO as control; two-tailed p-value; **: p<0,01; ***: 417 418 p<0,001; mean ± SD (n=6 independent experiments).

419 Figure 2: Acetylation levels of *T. gondii* histones after treatment with MC2125, MC2590 and MC2059.

The purified RH parasite samples were treated either with DMSO or MC2125, MC2590 and MC2059 (0,5 μ M). (A): Quantification of the signal for each indicated modified histone after treatment with DMSO (blue bars) or MC2125 (red bars). The signal was normalized to the signal given by the loading control (histone H3 Cterm, modified and unmodified). A Student's t-test was performed; two-tailed pvalue; ns: p>0,05; **: p<0,01; ***: p<0,001; mean ± SD (n=4 independent experiments). (B) Quantification of the signal for each indicated modified histone after treatment with DMSO (blue bars) or MC2590 (green bars). The signal was normalized to the signal given by the loading control (histone
H3 Cterm, modified and unmodified). A Student's t-test was performed; two-tailed p-value; ns: p>0,05;
: p<0,01; *: p<0,001; mean ± SD (n=4 independent experiments). (C) Quantification of the signal
for each indicated modified histone after treatment with DMSO (blue bars) or MC2059 (brown bars).
The signal was normalized to the signal given by the loading control (histone H3 Cterm, modified and
unmodified). A Student's t-test was performed; two-tailed p-value; ns: p>0,05; mean ± SD (n=3
independent experiments).

433 Figure 3: Effect of the compounds on the outcome of the acute and latent toxoplasmosis. (A): Effect 434 of MC2059, MC2125 and MC2590 treatment on the outcome of the acute disease. One day after 435 peritoneal injection of tachyzoites, mice were treated with different concentration of compounds once 436 a day for 5 days. The percentage of survival is represented for each day during 15 days. Mice treated 437 with DMSO (same regimen, blue line) are used as a negative control. Mice treated with Pyrimethamine 438 (black line) are used as a positive control. The percentage of surviving mice after treatment with MC2059 (30mg/kg, light green or 60mg/kg, dark green), MC2590 (30mg/kg, brown) and MC2125 439 440 (10mg/kg, red). A Log-rank (Mantel-Cox) test was performed; **: p< 0,01; ****: p< 0,0001; mean ± SD 441 (n=15 mice per group). (B): Treatment of the bradyzoite (latent) form of the parasite with the different 442 compounds. Latent bradyzoite cysts were obtained after 2 weeks of culture in primary brain cells and 443 then treated with 3 times the IC₅₀ for 7 days. The inhibition percentage was calculated when comparing the compound treated group to the control (DMSO treated cultures). Mean ± SD (n=3 independent 444 445 experiments).

Compounds	Structure	IC ₅₀
MC1742	NH NH NHOH	30 ± 8 nM
Pyrimethamine	NH ₂ H ₂ N	660 ± 230 nN
SAHA	H N O N N O N O H	247 ± 137 n№
MC2059	N-N NHOH	75 ± 9 nM
MC2590		23 ± 6 nM
MC2125	N N S O N O N O H O H	5 ± 1 nM

446 Table 1: IC₅₀ of selected hydroxamate-based compounds and pyrimethamine.

Table 2: IC₅₀ of the selected compounds in *T.gondii* Type I and Type II strains and toxicity of the selected compounds in HFF and HepG2 cells.

- 450 The IC_{50} was determined in at least three independent experiments. Selectivity index was calculated 451 based on the IC_{50} of the Type II strain. (¹) MC1742 IC_{50} in human fibroblasts (HFF cells) was determined
- 452 in (20). (²) The X indicates values that were not available.

453

	MC1742	MC2059	MC2590	MC2125
Type I IC₅₀ (nM)	39 ± 7	89 ± 6	30 ± 6	10 ± 3
Type II IC₅₀ (nM)	30 ± 8	75 ± 9	23 ± 6	5 ± 1
HFF IC₅₀ (nM)	3000 ⁽¹⁾	15800 ± 1536	34553 ± 9386	16313 ± 2529
HepG2 IC₅₀ (nM)	X ⁽²⁾	8364 ± 125	5531 ± 1879	198 ± 55
Selectivity index (IC50 HHF/ IC50 Type II)	100	211	1502	3263
Selectivity index (IC ₅₀ HepG2/ IC ₅₀ Type II)	X ⁽²⁾	111	240	40





Figure 1: Compounds potentially active against HDACs inhibit tachyzoite growth. (A) Calculated IC₅₀ for each tested compound. Intracellular tachyzoite of 456 457 458

455


the type II strain PTG-LUC GFP were treated for 40 hours at different concentrations (from 2µM to 2nM). The mean IC₅₀ for three biological replicates is presented on the graph together with SD. Compounds were ranked based on their calculated IC₅₀. The IC₅₀ values for Pyrimethamine (red), MC1742 (green), 459 MC2059 (purple), MC2590 (orange) and MC2125 (blue) are highlighted in the graph. Mean ± SD (n=3 independent experiments). (B) Effect of the compounds on RH tachyzoites on intracellular growth. Tachyzoite intracellular growth was measured after 36 hours of exposure to different compounds at 2 times the 460 461 IC₅₀ concentration. The average number of parasites per vacuole is used as a metric of parasite intracellular growth and measured by IFAs. Parasites treated

462 with DMSO (blue bars) are used as a control. We measured the effect of MC2059 (red bars), MC2590 (green bars), MC2125 (purple bars) on intracellular 463 growth. A Student's t-test was performed with the DMSO as control; two-tailed p-value; **: p<0,01; ***: p<0,001; mean ± SD (n=6 independent experiments).



466 Figure 2: Acetylation levels of *T. gondii* histones after treatment with MC2125, MC2590 and MC2059. The purified RH parasite samples were treated either
 467 with DMSO or MC2125, MC2590 and MC2059 (0,5 μM). (A): Quantification of the signal for each indicated modified histone after treatment with DMSO (blue

bars) or MC2125 (red bars). The signal was normalized to the signal given by the loading control (histone H3 Cterm, modified and unmodified). A Student's ttest was performed; two-tailed p-value; ns: p>0,05; **: p<0,01; ***: p<0,001; mean ± SD (n=4 independent experiments). (B) Quantification of the signal for
each indicated modified histone after treatment with DMSO (blue bars) or MC2590 (green bars). The signal was normalized to the signal given by the loading
control (histone H3 Cterm, modified and unmodified). A Student's t-test was performed; two-tailed p-value; ns: p>0,05; **: p<0,01; ***: p<0,001; mean ± SD
(n=4 independent experiments). (C) Quantification of the signal for each indicated modified histone after treatment with DMSO (blue bars) or MC2059 (brown
bars). The signal was normalized to the signal given by the loading control (histone H3 Cterm, modified). A Student's t-test was performed; two-tailed p-value; ns: p>0,05; **: p<0,01; ***: p<0,001; mean ± SD
(n=4 independent experiments). (C) Quantification of the signal for each indicated modified histone after treatment with DMSO (blue bars) or MC2059 (brown
bars). The signal was normalized to the signal given by the loading control (histone H3 Cterm, modified and unmodified). A Student's t-test was performed;
two-tailed p-value; ns: p>0,05; mean ± SD (n=3 independent experiments).



476

477 Figure 3: Effect of the compounds on the outcome of the acute and latent toxoplasmosis. (A): Effect of MC2059, MC2125 and MC2590 treatment on the 478 outcome of the acute disease. One day after peritoneal injection of tachyzoites, mice were treated with different concentration of compounds once a day for 5 days. The percentage of survival is represented for each day during 15 days. Mice treated with DMSO (same regimen, blue line) are used as a negative 479 480 control. Mice treated with Pyrimethamine (black line) are used as a positive control. The percentage of surviving mice after treatment with MC2059 (30mg/kg, light green or 60mg/kg, dark green), MC2590 (30mg/kg, brown) and MC2125 (10mg/kg, red). A Log-rank (Mantel-Cox) test was performed; **: p< 0,01; ****: 481 p< 0,0001; mean ± SD (n=15 mice per group). (B): Treatment of the bradyzoite (latent) form of the parasite with the different compounds. Latent bradyzoite 482 483 cysts were obtained after 2 weeks of culture in primary brain cells and then treated with 3 times the IC₅₀ for 7 days. The inhibition percentage was calculated 484 when comparing the compound treated group to the control (DMSO treated cultures). Mean \pm SD (n=3 independent experiments).